Literature DB >> 19210706

Erectile dysfunction in diabetes mellitus.

Lasantha S Malavige1, Jonathan C Levy.   

Abstract

INTRODUCTION: Type 2 diabetes is reaching pandemic levels and young-onset type 2 diabetes is becoming increasingly common. Erectile dysfunction (ED) is a common and distressing complication of diabetes. The pathophysiology and management of diabetic ED is significantly different to nondiabetic ED. AIM: To provide an update on the epidemiology, risk factors, pathophysiology, and management of diabetic ED.
METHOD: Literature for this review was obtained from Medline and Embase searches and from relevant text books. MAIN OUTCOME MEASURES: A comprehensive review on epidemiology, risk factors, pathophysiolgy, and management of diabetic ED.
RESULTS: Large differences in the reported prevalence of ED from 35% to 90% among diabetic men could be due to differences in methodology and population characteristics. Advancing age, duration of diabetes, poor glycaemic control, hypertension, hyperlipidemia, sedentary lifestyle, smoking, and presence of other diabetic complications have been shown to be associated with diabetic ED in cross-sectional studies. Diabetic ED is multifactorial in aetiology and is more severe and more resistant to treatment compared with nondiabetic ED. Optimized glycaemic control, management of associated comorbidities and lifestyle modifications are essential in all patients. Psychosexual and relationship counseling would be beneficial for men with such coexisting problems. Hypogonadism, commonly found in diabetes, may need identification and treatment. Maximal doses of phosphodiesterase type 5 (PDE5) inhibitors are often needed. Transurethral prostaglandins, intracavenorsal injections, vacuum devices, and penile implants are the available therapeutic options for nonresponders to PDE5 inhibitors and for whom PDE5 inhibitors are contraindicated. Premature ejaculation and reduced libido are conditions commonly associated with diabetic ED and should be identified and treated.
CONCLUSIONS: Aetiology of diabetic ED is multifactorial although the relative significance of these factors are not clear. A holistic approach is needed in the management of diabetic ED.

Entities:  

Mesh:

Year:  2009        PMID: 19210706     DOI: 10.1111/j.1743-6109.2008.01168.x

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  111 in total

1.  Effect of low-energy shockwave therapy on angiogenic factors in the penile tissue of diabetic rats.

Authors:  Mazhar Ortaç; Canan Küçükergin; Emre Salabaş; Şule Seçkin; Ateş Kadıoğlu
Journal:  Turk J Urol       Date:  2017-05-03

2.  Early-stage Type 2 Diabetes Mellitus Impairs Erectile Function and Neurite Outgrowth From the Major Pelvic Ganglion and Downregulates the Gene Expression of Neurotrophic Factors.

Authors:  Hotaka Matsui; Biljana Musicki; Nikolai A Sopko; Xiaopu Liu; Paula J Hurley; Arthur L Burnett; Trinity J Bivalacqua; Johanna L Hannan
Journal:  Urology       Date:  2016-09-14       Impact factor: 2.649

3.  Clinical significance and expression of microRNA in diabetic patients with erectile dysfunction.

Authors:  X I Jiang; Yong Luo; Shuli Zhao; Qichao Chen; Chao Jiang; Yutian Dai; Yun Chen; Zhigang Cao
Journal:  Exp Ther Med       Date:  2015-04-22       Impact factor: 2.447

Review 4.  [Conservative therapy of erectile dysfunction].

Authors:  M Trottmann; J Marcon; S Pompe; D Strobach; A J Becker; C G Stief
Journal:  Urologe A       Date:  2015-05       Impact factor: 0.639

5.  Mobilisation of endothelial progenitor cells: one of the possible mechanisms involved in the chronic administration of melatonin preventing erectile dysfunction in diabetic rats.

Authors:  Xue-Feng Qiu; Xiao-Xin Li; Yun Chen; Hao-Cheng Lin; Wen Yu; Run Wang; Yu-Tian Dai
Journal:  Asian J Androl       Date:  2012-02-27       Impact factor: 3.285

6.  MicroRNA-34a targets sirtuin 1 and leads to diabetes-induced testicular apoptotic cell death.

Authors:  Dan Jiao; Huan Zhang; Ziping Jiang; Wenlin Huang; Zhuo Liu; Zhaohui Wang; Yonggang Wang; Hao Wu
Journal:  J Mol Med (Berl)       Date:  2018-07-21       Impact factor: 4.599

7.  Erectile dysfunction and its management in patients with diabetes mellitus.

Authors:  Giuseppe Defeudis; Daniele Gianfrilli; Chiara Di Emidio; Riccardo Pofi; Dario Tuccinardi; Andrea Palermo; Andrea Lenzi; Paolo Pozzilli
Journal:  Rev Endocr Metab Disord       Date:  2015-10-26       Impact factor: 6.514

8.  Sexual dysfunctions in patients with diabetes: a study from Iran.

Authors:  Marzieh Ziaei-Rad; Mariam Vahdaninia; Ali Montazeri
Journal:  Reprod Biol Endocrinol       Date:  2010-05-18       Impact factor: 5.211

9.  A Review of the Pathophysiology and Novel Treatments for Erectile Dysfunction.

Authors:  George F Lasker; Jason H Maley; Philip J Kadowitz
Journal:  Adv Pharmacol Sci       Date:  2010

Review 10.  Vardenafil for the treatment of erectile dysfunction: an overview of the clinical evidence.

Authors:  Antonio Martín Morales; Vincenzo Mirone; John Dean; Pierre Costa
Journal:  Clin Interv Aging       Date:  2009-12-29       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.